Arcutis Biotherapeutics (ARQT) Expected to Release Quarterly Earnings on Tuesday

Key Points

• Arcutis Biotherapeutics is expected to report Q3 2026 results after market close on October 27. Analysts forecast earnings of $0.18 per share and revenue of $142.59 million; the earnings conference call is scheduled for November 3 at 4:00 p.m. ET.
• The company exceeded expectations in its latest quarter, reporting $0.11 EPS versus a $0.06 consensus and $129.86 million in revenue versus $118.85 million expected.
• Shares have risen 10.7% and analysts remain broadly bullish. Eight analysts rate ARQT a Buy and three rate it Hold, with a “Moderate Buy” consensus and an average price target of $38, compared with a recent opening price of $31.89.

Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) is expected to be announcing its Q3 2026 results after the market closes on Tuesday, October 27th. Analysts expect Arcutis Biotherapeutics to post earnings of $0.18 per share and revenue of $142.59 million for the quarter. Investors can find conference call details on the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 4:00 PM ET.

Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.11 EPS for the quarter, beating analysts' consensus estimates of $0.06 by $0.05. The firm had revenue of $129.86 million during the quarter, compared to the consensus estimate of $118.85 million. Arcutis Biotherapeutics had a return on equity of 15.05% and a net margin of 6.15%. On average, analysts expect Arcutis Biotherapeutics to post $0.43 EPS for the current fiscal year and $1.06 EPS for the next fiscal year.

Arcutis Biotherapeutics Trading Up 10.7%

Shares of ARQT opened at $31.89 on Tuesday. Arcutis Biotherapeutics has a one year low of $19.30 and a one year high of $33.01. The stock has a 50-day moving average price of $25.57 and a 200 day moving average price of $24.89. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.67 and a current ratio of 2.92. The company has a market capitalization of $4.01 billion, a P/E ratio of 137.24 and a beta of 1.57.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on ARQT shares. Needham & Company LLC upped their target price on Arcutis Biotherapeutics from $36.00 to $40.00 and gave the company a "buy" rating in a research report on Thursday, August 6th. Cantor Fitzgerald began coverage on Arcutis Biotherapeutics in a research note on Thursday, October 15th. They set an "overweight" rating and a $48.00 target price for the company. Wall Street Zen cut Arcutis Biotherapeutics from a "strong-buy" rating to a "buy" rating in a research note on Saturday, October 10th. Guggenheim raised their price target on shares of Arcutis Biotherapeutics from $38.00 to $44.00 and gave the stock a "buy" rating in a research report on Monday. Finally, Weiss Ratings lowered shares of Arcutis Biotherapeutics from a "hold (c)" rating to a "hold (c-)" rating in a research note on Wednesday, October 14th. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat, Arcutis Biotherapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $38.00.

Insiders Place Their Bets

In other news, insider Todd Watanabe sold 4,375 shares of the business's stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $26.12, for a total transaction of $114,275.00. Following the transaction, the insider directly owned 717,203 shares in the company, valued at $18,733,342.36. The trade was a 0.61% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Masaru Matsuda sold 3,674 shares of the business's stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $25.00, for a total transaction of $91,850.00. Following the transaction, the insider owned 112,508 shares in the company, valued at approximately $2,812,700. This represents a 3.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 83,953 shares of company stock valued at $2,143,291. 9.40% of the stock is currently owned by insiders.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc NASDAQ: ARQT is a biopharmaceutical company focused on developing and commercializing treatments for dermatologic conditions. The company concentrates on medical dermatology, with an emphasis on addressing diseases that can significantly affect patients' quality of life and for which additional treatment options are needed.

Arcutis's primary commercial product is ZORYVE (roflumilast), a topical phosphodiesterase-4 inhibitor available in multiple formulations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.